Investigator-Initiated Studies
Investigator-Initiated Studies supports independent researchers through Sarepta Therapeutics funding or study materials to answer medical and scientific questions in rare neuromuscular diseases.
Funder: Sarepta Therapeutics
Due Dates: Rolling (clinical and non-clinical proposals)
Funding Amounts: Funding or study materials; funding depends on study type and fair market value assessment
Summary: Supports investigator-led clinical and non-clinical research addressing scientific questions in rare neuromuscular diseases.
Key Information: The investigator—not Sarepta—initiates, conducts, and sponsors the study.
Description
Sarepta Therapeutics’ Investigator-Initiated Studies (IIS) program supports independent research in rare neuromuscular diseases through funding or study materials. Individual researchers, institutions, and groups can request support for clinical research, including observational studies, or non-clinical investigations. The program aims to enhance understanding and answer important medical and scientific questions within Sarepta’s core therapeutic areas, reflecting its commitment to precision genetic medicine for rare diseases.
Studies should have defined research objectives and address a valid scientific question. Sarepta’s subject matter experts and IIS committee assess proposals for scientific merit and alignment with the company’s strategic areas of interest. Investigators retain responsibility for initiating, conducting, and sponsoring their studies, with expectations for research integrity, data quality, and transparent dissemination of findings.
